Hikichi Eye Clinic, Sapporo, Japan.
Carl Zeiss Meditec Co., Ltd., Tokyo, Japan.
Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):1088-1095. doi: 10.1167/iovs.18-24522.
To investigate macular vascular alterations by using optical coherence tomography angiography (OCTA) in patients with a history of long-term anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (nAMD).
Japanese patients with nAMD with a history of long-term anti-VEGF monotherapy at study entry were studied retrospectively. OCTA images were obtained, and the vessel densities (mm-1) of the superficial capillary plexus, deep capillary plexus (DCP), choriocapillaris (CC), and the plexus foveal avascular zone area (mm2) were calculated.
One hundred twenty-four eyes (124 patients) were included. The mean ± standard deviation follow-up period between the first and last OCTA imaging sessions was 14.5 ± 3.1 months; the duration of the anti-VEGF monotherapy before the first OCTA imaging session was 68.0 ± 23.6 months, with a mean of 3.6 ± 3.0 injections during the follow-up period. The vessel densities of the DCP and CC significantly decreased (P = 0.001 and P = 0.009, respectively) from 10.62 ± 2.72 mm-1 and 11.84 ± 1.79 mm-1 to 9.44 ± 2.88 mm-1 and 11.18 ± 2.12 mm-1. Such findings were not observed in 63 control eyes.
The DCP and CC deteriorate during treatment. This information may guide future treatment strategies for nAMD, such as the need to protect the capillaries to maintain visual acuity after long-term treatment. Prospective, controlled trials are required to confirm our findings.
利用光相干断层扫描血管造影术(OCTA)研究长期接受抗血管内皮生长因子(VEGF)治疗的新生血管性年龄相关性黄斑变性(nAMD)患者的黄斑血管改变。
回顾性研究入组时接受长期抗 VEGF 单药治疗的 nAMD 日本患者。获取 OCTA 图像,并计算浅层毛细血管丛、深层毛细血管丛(DCP)、脉络膜毛细血管(CC)的血管密度(mm-1)和无血管区黄斑区(FAZ)面积(mm2)。
共纳入 124 只眼(124 例患者)。首次和末次 OCTA 成像之间的平均(±标准差)随访时间为 14.5 ± 3.1 个月;首次 OCTA 成像前抗 VEGF 单药治疗时间为 68.0 ± 23.6 个月,随访期间平均注射 3.6 ± 3.0 次。DCP 和 CC 的血管密度分别显著降低(P = 0.001 和 P = 0.009),从 10.62 ± 2.72 mm-1 和 11.84 ± 1.79 mm-1 降至 9.44 ± 2.88 mm-1 和 11.18 ± 2.12 mm-1。在 63 只对照眼中未观察到这种情况。
DCP 和 CC 在治疗过程中恶化。这些信息可能指导 nAMD 的未来治疗策略,例如在长期治疗后需要保护毛细血管以维持视力。需要进行前瞻性、对照试验来证实我们的发现。